AstraZeneca Acquires Global Rights (Excluding China) to COPD Drug from Sino Biopharmaceutical for $200M Upfront
AstraZeneca has acquired global rights, excluding China, to an experimental chronic obstructive pulmonary disease treatment called TQC3721. The deal with a subsidiary of Hong Kong-listed Sino Biopharmaceutical includes an upfront payment of $200 million.
Tickers: $AZN